Teva Agrees Not to Market Generic Temodar Until Federal Circuit Hears Schering's Appeal

摘要

Teva Pharmaceutical Industries Ltd. said it has agreed not to market a generic version of Schering-Plough Corp.'s brain tumor treatment Temodar (temozolomide) while U.S. Court of Appeals for the Federal Circuit considers the brand-name manufacturer's appeal of an adverse decision in patent litigation (Cancer Research Technology Ltd. v. Barr Laboratories Inc., D. Del., No. 07-cv-00457-SLR, agreement announced 3/17/10).